Phagenesis completes $42M Series D financing for swallowing disorder treatment expansion.

Phagenesis, a UK-based medical company, successfully completes $42M Series D financing. The company focuses on treating swallowing disorders with their Phagenyx® neurostimulation system, targeting neurological components disrupted due to brain injury. Funds will be used for expansion, development, US commercialization, European penetration, clinical trials, regulatory activities, and pipeline product research.